Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 30, 2017
Pharmacy Choice - News - U.S. FDA Final Approvals (Drugs & Devices) - May 30, 2017

Pharmacy News

 U.S. FDA Final Approvals (Drugs & Devices)
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
<< Back     Articles(s): 26 - 38 of 38     Go To Page:

5/24/17 - FDA Approves First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. "This is an important first for the cancer community," said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncolog
5/24/17 - FDA approves Merck's bladder cancer drug
The FDA has approved two new indications for Merck's Keytruda (pembrolizumab), the company's anti-PD-1 therapy, for bladder cancer...
5/24/17 - FDA approves Roche's Actemra/RoActemra (tocilizumab) for giant cell arteritis
-Actemra/RoActemra is the first FDA- approved treatment for adults with giant cell arteritis. -FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA. "Today's FDA decision means people living with giant cell arteritis will, for the first time, have an FDA- approved treatment option for this debili
5/24/17 - Merck Says FDA Approves New Indication For KEYTRUDA
WHITEHOUSE STATION- Merck said that the U.S. Food and Drug Administration has approved a new indication for KEYTRUDA, the company's anti-PD-1 therapy. KEYTRUDA is now indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient. solid tumors that have...
5/24/17 - NucleusHealth? Receives FDA 510(k) Clearance for Nucleus.io?
NucleusHealth?, advancing clinical practice and patient care through innovative medical image management and interpretation, has received U.S. Food and Drug Administration 510 clearance for its Nucleus.io technology. Nucleus.io is a web-based, scalable and secure cloud platform for medical image management. "We're excited to bring our latest adv
5/24/17 - Orchid Pharma gets US FDA approval for Aripiprazole tablet [India Infoline News Service]
Orchid Pharma Limited, in its BSE filing on Wednesday, announced that it has received Abbreviated New Drug Application approval from US FDA for Aripiprazole Tablets USP, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. Orchid Pharma Limited, in its BSE filing on Wednesday, announced that it has received Abbreviated New Drug Application approval from US
5/24/17 - Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test [Sport360]
Roche announced approval of the VENTANA PD-L1 Assay by the US Food and Drug Administration as a complementary diagnostic3 to provide PD-L1 status for patients with locally advanced or metastatic urothelial carcinoma 4 who are being considered for treatment with the FDA- approved anti-PD-L1 immunotherapy IMFINZI. "We are very pleased the VENTANA PD
5/24/17 - SCIEX Announces the First FDA-Cleared Vitamin D Assay Kit for Mass Spectrometry
SCIEX Diagnostics, the in vitro diagnostics division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced today the first and only FDA- cleared LC-MS based Vitamin D assay kit, the Vitamin D 200 M Assay, exclusively for the SCIEX Topaz? System. The Topaz System is a fully integrated LC-MS platform driven by Clea
5/23/17 - FDA Approves First Drug to Specifically Treat Giant Cell Arteritis
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. This new indication provides the first FDA- approved therapy, specific to this type of vasculitis. "We expedited the development and review of this application because this drug fulfills a critical need for patients with this serious
5/23/17 - FDA Approves Merck's KEYTRUDA (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved a new indication for KEYTRUDA , the company s anti-PD-1 therapy. KEYTRUDA is now indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismat
5/23/17 - FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency
BETHPAGE, N.Y., May 23, 2017/ PRNewswire-USNewswire/ In an unprecedented, fast-tracked review, the Food and Drug Administration approved the use of pembrolizumab immunotherapy for patients with advanced pancreatic cancers who have a defect in their capacity to repair DNA. Support from the Lustgarten Foundation was critical to the success of the c
5/23/17 - FDA approves Roche's Actemra/RoActemra (tocilizumab) for giant cell arteritis
-Actemra/RoActemra is the first FDA- approved treatment for adults with giant cell arteritis. Basel Roche today announced that the U.S. Food and Drug Administration has approved Actemra/RoActemra) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition. "Today's FDA decision means people living with giant cell
5/23/17 - Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Other Events
Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Other Events Item 8.01 Other Events On May 22, 2017, Immune Therapeutics, Inc., a Florida corporation (the Company) issued a press release announcing that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM in Nigeria.
<< Back     Articles(s): 26 - 38 of 38     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415